Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is headquartered in Watertown, Massachusetts.
52W High
$61.07
52W Low
$13.70
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
4.06
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
1.11
Ownership
BalancedSource: Overview
Insiders (1–5% typical)
38.21%
Institutions (25–75% balanced)
65.04%
Shares Outstanding
18,712,100
Float
9,741,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
4.14
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.29%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
-1.9603
Previous
-1.9952
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025